Servier Pharmaceuticals shared a post on LinkedIn:
“One year ago, Servier brought the first and only FDA–approved targeted therapy for Grade 2 IDH-mutant glioma to patients in the U.S., marking the first significant treatment breakthrough for this relentless condition in over two decades.
Today, our commitment remains stronger than ever as we continue to drive progress forward for patients and families affected by glioma and other IDH-mutated cancers. Learn more about our ongoing efforts here.”
More posts featuring Servier Pharmaceuticals.